BB 3Alternative Names: BB-3; Refanalin
Latest Information Update: 03 Mar 2016
At a glance
- Originator Angion Biomedica
- Class Small molecules
- Mechanism of Action Hepatocyte growth factor stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Renal failure
- No development reported Heart failure
- Discontinued Hepatic fibrosis; Myocardial infarction; Stroke